Product Images Clopidogrel

NuCare Pharmaceuticals, Inc. provides pharmaceutical products including Elessa 28 and Clopidogrel 75mg tablets. The lot number, NDC, serial number, and expiry date are stated on the label. Consumers are advised to refer to the manufacturer's label for a full list of ingredients. In case of side effects, one may report to FDA or contact a doctor for medical advice. Children should not access the product which must also be stored under controlled temperature between 59-86°F.*

This is a graph showing the cumulative event rate for fatal or non-fatal vascular events for patients taking Aspirin versus Clopidogrel Bisulfate. The graph shows percentages ranging from 0 to 16% on the y-axis, and time in months on the x-axis. The P-value of 0.045 suggests a statistically significant difference between the two treatments.*

This is a comparison of the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke between the placebo (with aspirin) and clopidogrel bisulfate (with aspirin) groups over a follow-up period of 1-12 months. Other standard therapies were also used, as appropriate. The results show that clopidogrel bisulfate, when taken with aspirin, had a statistically significant lower cumulative event rate than placebo.*

This is a report on the number of deaths observed before the first discharge in a clinical trial comparing a placebo to a medication called Clopidogrel. There were 1845 deaths (8.1%) in the placebo group and 1726 deaths (7.5%) in the Clopidogrel group, indicating a 7% proportional risk reduction (p=0.03). The x-axis shows the days since randomization (up to 28 days).*

The given text seems to be a statistical data comparison between placebo and clopidogrel in reducing the risk of death, re-infraction or stroke up to 28 days after discharge. The result shows that clopidogrel has a 9% proportional risk reduction compared to placebo, with a p-value of 0.002. However, it is unclear what the text "T4 5 %5 o randomization" means in this context.*

This appears to be a table or chart related to the qualifying conditions for stroke and PAD, with data for patients receiving either clopidogrel and aspirin or bisulfate. There are columns for the years 2006-2013, with a row for each of the three conditions (stroke, PAD, and overall) and a separate row for the percentage of patients receiving each treatment. There is also a row for "favors clopidogrel bisulfate" and "favors aspirin", although it is not clear how these are calculated or what they refer to. The table ends with a row labeled "hazard ratio", which may be a measure of treatment efficacy or risk. Without additional context it is difficult to fully interpret this data.*